



## CEU PROGRAM DESCRIPTION

### 1. Title of Presentation:

An Introduction to TMS

### 2. Description of Program:

Approved by the FDA in 2008 for the treatment of depression, Transcranial Magnetic Stimulation has gained interest and popularity with its acceptance for reimbursement by Medicare and most commercial health insurance carriers. Transcranial Magnetic Stimulation (TMS) is a novel approach that extends the spectrum of successful treatment beyond what has been provided by medication management and traditional psychotherapy.

In this presentation, the fundamentals of TMS for depression are reviewed. The limits of antidepressant medication are considered in terms of treatment success and failure and side effects. The logistics and mechanics of TMS are covered with emphasis on the differences between TMS and ECT. Some outcomes data is shared along with the limitations to outcomes research in TMS.

### 3. Program Objectives:

- a. At the end of this presentation the participant will appreciate several significant distinctions between Transcranial Magnetic Stimulation (TMS) and Electro-Convulsive Therapy (ECT).
- b. At the end of this presentation the participant will appreciate the mechanism of action of TMS and the logistics of TMS treatment.
- c. At the end of this presentation the participant will appreciate common characteristics of those who seek and qualify for Transcranial Magnetic Stimulation.

### 3. Bio of Presenter:

David McNeil, M.D. is a psychiatrist in private practice with offices in Buffalo Grove and downtown Chicago. Dr. McNeil attended Amherst College in Massachusetts and the University of Cincinnati College of Medicine. He completed his residency in psychiatry at Rush University Medical Center in Chicago in 1989. Dr. McNeil has served on Regional and National Advisory Panels for a number of pharmaceutical companies and as a spokesperson for the National Institute of Mental Health.